N26 THE REALITY LAYER
How Null Results Build Brands
A company that promises to publish the result, not its direction, is making a different kind of claim.
IN THIS NOTE · MARCH 2026
Consumer health brands usually treat an unfavorable result as a marketing failure. That instinct prevents them from building the asset customers say they want: a trustworthy system for learning what actually works.
Precommitment changes incentives
A preregistered protocol defines endpoints, methods and analysis before outcomes are visible. It limits the temptation to search for a flattering subgroup or switch the primary story after the fact.
A public reporting rule goes further. It tells customers and researchers that a null finding will not disappear simply because it is inconvenient.
Negative evidence has product value
A null result can narrow claims, improve formulation, identify a poor endpoint or reveal that the product serves a smaller population than expected. Each lesson can reduce future waste.
The commercial value comes from demonstrating that measurement is not theatre. Trust can compound across several honest studies even when every individual result is not exciting.
Be precise about what failed
Null does not mean useless, and positive does not mean proven. Sample size, adherence, measurement error and study design determine the inference. Reporting should show confidence intervals, limitations and what the result changes.
The brand earns credibility by refusing to turn either outcome into more than the design supports.
Write the reporting policy before enrollment
Transparency is credible when it is costly to reverse. The study record should identify the primary question, endpoints, analysis population, stopping rules and publication commitment before outcomes are known. A brand can still correct mistakes or explain deviations, but it should preserve the original plan and state why the change occurred. This limits the quiet movement from a failed primary endpoint to an exciting subgroup discovered after the fact.
The policy must also define what will be released. A promotional summary is not enough. Readers need the protocol, participant flow, effect estimates, uncertainty, adverse events, deviations and limitations at a level appropriate to the study. Raw personal data may remain protected while analysis code or de-identified aggregates become inspectable. The objective is not maximal disclosure; it is enough evidence to understand what was tested and what the result can support.
Use the null to narrow the product
A null result is commercially useful when it changes a decision. It may remove a claim, identify a subgroup that needs a new confirmatory study, expose low adherence, reveal an implausible endpoint or show that an ingredient effect does not survive the finished formulation. The team should publish that decision alongside the result. Otherwise transparency becomes theatre: information is released, but the product and message remain untouched.
Over several cycles, this behavior creates a brand asset more durable than one positive study. Customers, researchers and partners learn that the company has an evidence threshold and will accept an inconvenient answer. The payoff is not guaranteed, and honest reporting can reduce short-term conversion. The thesis is that durable trust comes from a demonstrated learning system, not from the improbable claim that every experiment confirms the marketing plan.
- Preregister endpoints and analysis.
- Publish a reporting rule before recruitment.
- Explain what a null result changes in the product or claim set.
I would reconsider if selective positive-result marketing produced more durable trust than transparent reporting across repeated product cycles.
Primary and institutional sources used as the grounding layer. Interpretation and synthesis are Luca's.
01